StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$398.08−23.91 (-5.67%)

Close on Nov 18, 2026Market cap $9.20BP/E –Yield –

Madrigal Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Madrigal Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$322.62M. For fiscal 2025 it was -$300.10M. The highest annual figure on record is $79.30M in fiscal 2009.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$300.10M–
FY2024Dec 31, 2024-$497.88M–
FY2023Dec 31, 2023-$380.50M–
FY2022Dec 31, 2022-$293.57M–
FY2021Dec 31, 2021-$242.48M–
FY2020Dec 31, 2020-$206.67M–
FY2019Dec 31, 2019-$94.97M–
FY2018Dec 31, 2018-$40.68M–
FY2017Dec 31, 2017-$32.06M–
FY2016Dec 31, 2016-$25.22M–
FY2015Dec 31, 2015-$3.23M–
FY2014Dec 31, 2014-$83.95M–
FY2013Dec 31, 2013-$87.56M–
FY2012Dec 31, 2012-$60.94M–
FY2011Dec 31, 2011-$45.43M–
FY2010Dec 31, 2010-$36.90M-146.5%
FY2009Dec 31, 2009$79.30M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$56.31M–
Q1 FY2026Mar 31, 2026-$92.72M–
Q4 FY2025Dec 31, 2025-$59.61M–
Q3 FY2025Sep 30, 2025-$113.98M–
Q2 FY2025Jun 30, 2025-$47.20M–
Q1 FY2025Mar 31, 2025-$79.31M–
Q4 FY2024Dec 31, 2024-$67.00M–
Q3 FY2024Sep 30, 2024-$116.30M–
Q2 FY2024Jun 30, 2024-$162.54M–
Q1 FY2024Mar 31, 2024-$152.04M–
Q4 FY2023Dec 31, 2023-$117.18M–
Q3 FY2023Sep 30, 2023-$98.53M–
Q2 FY2023Jun 30, 2023-$86.45M–
Q1 FY2023Mar 31, 2023-$78.34M–
Q4 FY2022Dec 31, 2022-$85.30M–
Q3 FY2022Sep 30, 2022-$80.41M–
Q2 FY2022Jun 30, 2022-$70.27M–
Q1 FY2022Mar 31, 2022-$57.59M–
Q4 FY2021Dec 31, 2021-$64.60M–
Q3 FY2021Sep 30, 2021-$63.16M–
Q2 FY2021Jun 30, 2021-$61.74M–
Q1 FY2021Mar 31, 2021-$52.98M–
Q4 FY2020Dec 31, 2020-$59.56M–
Q3 FY2020Sep 30, 2020-$58.79M–
Q2 FY2020Jun 30, 2020-$50.33M–
Q1 FY2020Mar 31, 2020-$38.01M–
Q4 FY2019Dec 31, 2019-$29.95M–
Q3 FY2019Sep 30, 2019-$24.20M–
Q2 FY2019Jun 30, 2019-$22.70M–
Q1 FY2019Mar 31, 2019-$18.12M–
Q4 FY2018Dec 31, 2018-$14.45M–
Q3 FY2018Sep 30, 2018-$11.33M–
Q2 FY2018Jun 30, 2018-$7.83M–
Q1 FY2018Mar 31, 2018-$7.07M–
Q4 FY2017Dec 31, 2017-$8.91M–
Q3 FY2017Sep 30, 2017-$8.64M–
Q2 FY2017Jun 30, 2017-$8.44M–
Q1 FY2017Mar 31, 2017-$6.08M–
Q4 FY2016Dec 31, 2016-$7.76M–
Q3 FY2016Sep 30, 2016-$14.09M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?